Modulo Bio

This funding will support IND-enabling studies and bring our CSF1R inhibitor closer to clinical trials. We're incredibly proud of our team's work and grateful for @TheADDF's belief in our vision to deliver new hope to patients with devastating neurodegenerative conditions.

We’re thrilled to announce that @ModuloBio has secured a $4.8M strategic investment from the @TheADDF ! This funding will accelerate the development of our novel CSF1R inhibitor targeting Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS).

Immense gratitude to the @alsassociation team making this possible. Press Release: einpresswire.com/article/783811…

This @alsassociation grant will support critical preclinical studies needed for our IND filing and help validate our identified biomarkers—to identify patients likely to respond to treatment.

Exciting news! Modulo Bio has secured a $500k research grant from @alsassociation's Lawrence and Isabel Barnett Drug Development Program to advance our groundbreaking work in ALS and FTD treatment.

And hear directly from Mike and Scott on Near Frontier nearfrontier.castos.com/episodes/repro…

We’re so excited to partner with the Modulo team and our friends at @Initialized, @BuildersVC, @refactor, @WizLikeWizard, and others as we build the map and key for CNS diseases. You can read more here medium.com/cantos-venture…

@Initialized @cantos @spacecadet @refactor @BuildersVC @biovergehq 7/7: Join us on our journey as we strive to make a profound impact on neurodegenerative disease treatment. Learn more at modulo.bio.

@Initialized @cantos @spacecadet @refactor @BuildersVC @biovergehq 6/7: But we're not just studying these powerful cells. Our end goal is to develop therapeutics that reprogram microglia from harmful to neuroprotective states. Because ultimately, this is about getting treatments to patients.

1/7: We're thrilled to emerge from stealth and announce @ModuloBio! We are relentlessly focused on harnessing the brain’s immune system and the power of microglia to combat neurodegenerative diseases like ALS, FTD, Alzheimer’s, and Parkinson’s.